| Bikashagarwal Inc. | |
|
8733 W 400 N Michigan City IN 46360-9330 | |
| (219) 861-8740 | |
| Not Available |
| Full Name | Bikashagarwal Inc. |
|---|---|
| Speciality | Internal Medicine |
| Location | 8733 W 400 N, Michigan City, Indiana |
| Authorized Official Name and Position | Bikash Agarwal (OWNER) |
| Authorized Official Contact | 2192298620 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Bikashagarwal Inc. 8733 W 400 N Michigan City IN 46360-9330 Ph: (219) 229-8620 | Bikashagarwal Inc. 8733 W 400 N Michigan City IN 46360-9330 Ph: (219) 861-8740 |
| NPI Number | 1255610697 |
|---|---|
| Provider Enumeration Date | 08/16/2011 |
| Last Update Date | 03/22/2023 |
| Medicare PECOS PAC ID | 8729258702 |
|---|---|
| Medicare Enrollment ID | O20110830000620 |
News Archive
Researchers from the Universitat Politècnica de València, the Hospital General de Valencia and the Ophthalmology Unit of the Foundation for the Health and Biomedical Research of the Comunitat Valenciana (FISABIO-Oftalmología Médica) have developed a new software to aid cardiovascular risk diagnosis based on fundus image processing.
Rehabilitation is recommended for many patients following a hospital stay for acute heart disease. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztebl int 112: 527-34) Axel Schlitt et al. show that this improves prognosis for heart disease and can thus reduce patient mortality.
In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.
Researchers at the Institute of Materials Science of the Universitat de València, in consortium with various European companies and institutions, are developing a system based on photonic biosensors for rapid diagnosis of food allergies.
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255610697 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 01048288A (Indiana) | Primary |
| Provider Name | Bikash Agarwal |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093700825 PECOS PAC ID: 0547258246 Enrollment ID: I20040503000716 |
News Archive
Researchers from the Universitat Politècnica de València, the Hospital General de Valencia and the Ophthalmology Unit of the Foundation for the Health and Biomedical Research of the Comunitat Valenciana (FISABIO-Oftalmología Médica) have developed a new software to aid cardiovascular risk diagnosis based on fundus image processing.
Rehabilitation is recommended for many patients following a hospital stay for acute heart disease. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztebl int 112: 527-34) Axel Schlitt et al. show that this improves prognosis for heart disease and can thus reduce patient mortality.
In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.
Researchers at the Institute of Materials Science of the Universitat de València, in consortium with various European companies and institutions, are developing a system based on photonic biosensors for rapid diagnosis of food allergies.
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.
› Verified 5 days ago
| Provider Name | Carolyn Mae Blouir |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174024939 PECOS PAC ID: 6709148208 Enrollment ID: I20180321001774 |
News Archive
Researchers from the Universitat Politècnica de València, the Hospital General de Valencia and the Ophthalmology Unit of the Foundation for the Health and Biomedical Research of the Comunitat Valenciana (FISABIO-Oftalmología Médica) have developed a new software to aid cardiovascular risk diagnosis based on fundus image processing.
Rehabilitation is recommended for many patients following a hospital stay for acute heart disease. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztebl int 112: 527-34) Axel Schlitt et al. show that this improves prognosis for heart disease and can thus reduce patient mortality.
In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.
Researchers at the Institute of Materials Science of the Universitat de València, in consortium with various European companies and institutions, are developing a system based on photonic biosensors for rapid diagnosis of food allergies.
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.
› Verified 5 days ago
News Archive
Researchers from the Universitat Politècnica de València, the Hospital General de Valencia and the Ophthalmology Unit of the Foundation for the Health and Biomedical Research of the Comunitat Valenciana (FISABIO-Oftalmología Médica) have developed a new software to aid cardiovascular risk diagnosis based on fundus image processing.
Rehabilitation is recommended for many patients following a hospital stay for acute heart disease. In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztebl int 112: 527-34) Axel Schlitt et al. show that this improves prognosis for heart disease and can thus reduce patient mortality.
In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.
Researchers at the Institute of Materials Science of the Universitat de València, in consortium with various European companies and institutions, are developing a system based on photonic biosensors for rapid diagnosis of food allergies.
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.
› Verified 5 days ago
Healthpartners Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1225 E Coolspring Ave, Michigan City, IN 46360 Phone: 219-879-6531 Fax: 219-878-5015 | |
Healthlinc - Michigan City Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 200 Alfred St, Michigan City, IN 46360 Phone: 219-413-5100 | |
Smart Physician Systems Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 10176 W 400 N Ste C, Michigan City, IN 46360 Phone: 219-805-5333 Fax: 219-873-0001 | |
Chest Clinic, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 10176 W 400 N, Suite B, Michigan City, IN 46360 Phone: 219-878-5864 Fax: 219-878-0632 | |
Lakeshore Bone & Joint Institute, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1225 E Coolspring Ave Ste 2f, Michigan City, IN 46360 Phone: 219-921-1444 Fax: 219-921-0533 | |
Healthlinc, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 710 Franklin St Ste 200, Michigan City, IN 46360 Phone: 219-872-6200 | |
Contri Medical Corporation Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 217 West Homer Street, Michigan City, IN 46360 Phone: 219-872-2101 Fax: 219-878-8017 |